Table 2.
Baseline-, disease-, and treatment characteristics of 42 patients with Her-2-negative metastatic breast cancer had received either single-agent pegylated liposomal doxorubicin (PLD) or single-agent taxane in first-line chemotherapy with subsequent crossover.
| Characteristic | First Line PLD (n = 23) | First Line Taxane (n = 19) | p |
|---|---|---|---|
| Median age at treatment initiation | 61.5 | 59.8 | 0.74 |
| Breast cancer type | |||
| Luminal A (%) | 8 (35) | 6 (32) | 1 |
| Luminal B (%) | 12 (52) | 11 (58) | 0.76 |
| Triple-negative breast cancer (%) | 3 (13) | 2 (11) | 1 |
| Receptor Status | |||
| ER-positive (%) | 20 (87) | 17 (89) | 1 |
| PR-positive (%) | 18 (78) | 15 (79) | 1 |
| M-stage at primary diagnosis | |||
| M0/cMx (%) | 18 (78) | 16 (84) | 0.71 |
| M1 (%) | 5 (22) | 3 (16) | |
| Relevant comorbidity | |||
| Heart/Cardiovascular (%) | 2 (9) | 1 (5) | 1 |
| Pulmonary (%) | 3 (13) | 0 (0) | 0.24 |
| Diabetes (%) | 3 (13) | 2 (11) | 1 |
| Arterial hypertension (%) | 6 (26) | 7 (37) | 0.52 |
| Other (%) | 8 (35) | 3 (16) | 0.29 |
| Metastases at diagnosis of MBC | |||
| Bone (%) | 17 (74) | 10 (53) | 0.11 |
| Lung (%) | 9 (39) | 5 (26) | 0.51 |
| Liver (%) | 5 (22) | 6 (32) | 0.50 |
| Pleural (%) | 2 (9) | 2 (11) | 1 |
| CNS (%) | 1 (4) | 1 (5) | 1 |
| Peritoneal/abdominal (%) | 2 (9) | 2 (11) | 1 |
| Other sites (%) | 11 (48) | 11 (58) | 0.55 |
| Visceral disease (%) | 12 (52) | 10 (53) | 1 |
| 1–2 organs involved (%) | 15 (65) | 12 (63) | 1 |
| ≥3 organs involved (%) | 8 (35) | 7 (37) | -- |
| Primary treatment | |||
| Breast conservative surgery (%) | 12 (52) | 11 (58) | 0.76 |
| Breast ablative surgery (%) | 6 (26) | 7 (37) | 0.52 |
| Sentinel node resection (%) | 10 (43) | 7 (37) | 0.76 |
| Axillar revision (%) | 11 (48) | 10 (53) | 1 |
| Neoadjuvant chemotherapy | |||
| Any (%) | 1 (4) | 3 (16) | 0.31 |
| Neoadjuvant taxanes (%) | 1 (4) | 2 (11) | 0.58 |
| Neoadjuvant anthracycline (%) | 1 (4) | 3 (16) | 0.31 |
| Adjuvant chemotherapy | |||
| Any (%) | 7 (30) | 10 (53) | 0.21 |
| Taxane (%) | 3 (13) | 4 (21) | 0.68 |
| Anthracycline (%) | 6 (26) | 8 (42) | 0.33 |
| Adjuvant endocrine therapy | |||
| Any (%) | 13 (57) | 14 (74) | 0.34 |
| Minimum of 5 years (%) | 7 (30) | 8 (42) | 0.52 |
| Radiotherapy | |||
| Adjuvant RT (%) | 14 (61) | 16 (84) | 0.17 |
| RT for MBC before first line (%) | 14 (61) | 15 (79) | 0.32 |
| Systemic treatment for MBC | |||
| Endocrine therapy before first CT (%) | 17 (74) | 13 (68) | 0.74 |
| cdk4/6 inhibitor before first CT (%) | 9 (39) | 4 (21) | 0.32 |
| Choice of taxane: paclitaxel weekly (%) | 21 (91) | 17 (89) | |
| Choice of taxane: docetaxel q3w (%) | 2 (9) | 2 (11) | 1 |
| Median endocrine lines before first CT | 2 | 1 | 0.08 |
| Median total treatment lines | 5 | 5 | 0.84 |
| Median subsequent treatment lines | 3 | 3 | 0.36 |
| Bisphosphonate/denosumab (%) | 15 (65) | 11 (58) | 0.75 |
BC = breast cancer; CNS = central nervous system; CT = chemotherapy; ER = estrogen receptor; Her-2 = human epidermal growth factor receptor 2; MBC = metastatic breast cancer; n = number; p = p-value; PLD = pegylated liposomal doxorubicin; PR = progesterone receptor; n = number; RT = radiotherapy.